Get started
Author

Michael Stahl

Observed names: M Stahl, M. Stahl, Michael J. Stahl, Stahl, Michael
ORCID: 0009-0004-4264-6405
Observed ORCID: 0009-0004-4264-6405
OpenAlex ID: A5111060443
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
2018 · Maren Knödler, Justus Körfer, et al. · British Journal of Cancer · 89
PDF
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
2008 · on behalf of the German CUP Study Group, G Huebner, et al. · British Journal of Cancer · 86
PDF
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
2024 · Alwin Krämer, Tilmann Bochtler, et al. · The Lancet · 83
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
2022 · Sylvie Lorenzen, Peter Thuss-Patience, et al. · European Journal of Cancer · 58
Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial
2015 · John D. Hainsworth, Gedske Daugaard, et al. · Cancer · 47
PDF
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations
2024 · Daniel L. Hertz, Markus Joerger, et al. · European Journal of Cancer · 31
PDF
Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108
2016 · K. Jordan, T. Luetkens, et al. · European Journal of Cancer · 28
PDF
Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer
1991 · Hansjochen Wilke, Peter Preusser, et al. · Cancer Chemotherapy and Pharmacology · 27
Phase II Trial of Capecitabine and Oxaliplatin in Patients with Adeno- and Undifferentiated Carcinoma of Unknown Primary
2009 · Katharina Schuette, Gunnar Folprecht, et al. · Oncology Research and Treatment · 21
Adjuvant Aspirin Treatment in PIK3CA -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
2025 · Ulrich Güller, Stefanie Hayoz, et al. · Clinical Cancer Research · 20
LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
2023 · L. Mileshkin, T. Bochtler, et al. · Annals of Oncology · 20
PDF
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
2020 · Sylvie Lorenzen, Peter C. Thuss-Patience, et al. · Journal of Clinical Oncology · 20
Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
2004 · Wolf K??ster, G Stamatis, et al. · Clinical Drug Investigation · 13
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
2024 · Ulrich Ronellenfitsch, Juliane Friedrichs, et al. · JAMA Network Open · 12
PDF
Influence of Taxanes on Treatment Sequence in Gastric Cancer
2019 · Sylvie Lorenzen, Michael Stahl, et al. · Oncology Research and Treatment · 12
Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
2020 · Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP Group, Gunnar Folprecht, et al. · British Journal of Cancer · 7
PDF
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study.
2018 · Sylvie Lorenzen, Peter C. Thuss-Patience, et al. · Journal of Clinical Oncology · 3
SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group
2023 · L. Weiss, V. Heinemann, et al. · Annals of Oncology · 2
PDF
Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.
2019 · Alwin Krämer, Alexander Stein, et al. · Journal of Clinical Oncology · 2
Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)
2018 · M. Haas, D. Waldschmidt, et al. · Annals of Oncology · 1
Hämatologie und Onkologie
2016 · Karl-Anton Kreuzer, Jörg Beyer, et al. · Thieme eBooks · 1
Contents of Forthcoming Issues · Themenvorschau
2009 · Cornelius Mensing, Elisabeth Livingstone, et al. · Oncology Research and Treatment · 1
PDF
Supplementary Table S3 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
2025 · Ulrich Güller, Stefanie Hayoz, et al.
Supplementary Figure S2 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
2025 · Ulrich Güller, Stefanie Hayoz, et al.
Supplementary Figure S1 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
2025 · Ulrich Güller, Stefanie Hayoz, et al.
Works count: 42
Citation count: 584
H-index: 13
I10-index: 15
Year
Topic
Type